The pathway to commercialization for nanomedicine

This article summarizes some of the major obstacles that nano-enabled medical drugs and devices may face on the road to commercialization. This includes the cost of getting a drug through the U.S. Food and Drug Administration's approval process, questions that investors still harbor about the long-term economic impact of nanomedicine, and questions about the potential toxicity of some kinds of manufactured nanomaterials.